Effects of Chronic Genistein Treatment in Mammary Gland, Uterus, and Vagina

Rimoldi, Guillermo; Christoffel, Julie; Seidlová-Wuttke, Dana; Jarry, Hubertus; Wuttke, W.

doi:10.1289/ehp.9367

Cited by 65 publications

(51 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been recently confirmed that progestogen exposure might negatively influence reproductive health, in terms of fertility and sexual differentiation [38]. Additionally, it is acknowledged that the uterus and mammal glands are negatively affected by the estrogens used in hormone therapy [39]. Through the present study, hormone administration to pregnant women was for the first time assessed and signifi- [40].…”

Section: Macrosomia Risk Factorsmentioning

confidence: 70%

Rates and Risk Factors in Macrosomic Newborns among Non-Diabetic Parturients at Tiznit City, Morocco: A Case-Control Study

Korrida¹

2017

OALib

View full text Add to dashboard Cite

Background: The present study was elaborated to assess the prevalence of high birth weight and its related risk factors for macrosomic infants among women in Southern Morocco. Methods: A case-control study was conducted on term singleton live-births, with no morbidity or malformation, of a sample of (n = 78) nulliparous and multiparous non-diabetic women delivering at Hassan I Provincial Hospital. Cases included neonates ≥ 4000 g, whereas controls comprised infants with birth weight between 2500 and 3999 g. Personal information was collected from pregnant women using a structured questionnaire, and through a review of their medical records. Associations between exposure and dependent variable (macrosomia) were calculated using linear and logistic regressions. Results: Macrosomia prevalence was 35.89%. Mean birth weight in cases was 4310.71 ± 246.96 g, and in controls 3076.00 ± 533.97 g. Maternal lifestyle behaviors, as well as sociodemographic factors were not associated with macrosomia, except for maternal age over 40 years (OR: 4.27, 95% CI: 0.98 -18.68). Logistic regression model analysis indicated that macrosomia was strongly associated with hormone therapy (adjusted OR: 18.83, 95% CI: 1.54 -214.51), followed by obesity/overweight history (adjusted OR: 7.94, 95% CI: 1.52 -41.41), and pre-pregnancy BMI ≥ 25 Kg/m 2 for pooled overweight and obesity factor (adjusted OR: 5.24, 95% CI: 1.54 -17.82). Conclusion: Pre-pregnancy BMI > 25 kg/m², pre-existing overweight/ obesity, and hormone therapy should be considered as independent risk factors for fetal macrosomia and require more attention from health professionals.

show abstract

Section: Macrosomia Risk Factorsmentioning

confidence: 70%

Rates and Risk Factors in Macrosomic Newborns among Non-Diabetic Parturients at Tiznit City, Morocco: A Case-Control Study

Korrida¹

2017

OALib

View full text Add to dashboard Cite

show abstract

“…Our observed effect of genistein on uterine weight is consistent with previous reports in the literature. For example, Rimoldi et al 28 showed in OVX rats that a 3-month oral regimen of genistein (54 mg=kg=day) significantly increased uterine weight. Our observed increase in femur weight was also in accord with previous studies demonstrating that genistein (administered for either 3 or 7 weeks) increased bone formation in OVX rats.…”

mentioning

confidence: 99%

Genistein Induces Estrogen-Like Effects in Ovariectomized Rats but Fails to Increase Cardiac GLUT4 and Oxidative Stress

Al‐Nakkash

Markus²,

Batia³

et al. 2010

Journal of Medicinal Food

View full text Add to dashboard Cite

This study aimed to determine whether a 2-week genistein treatment induced estrogen-like effects in ovariectomized (OVX) Sprague-Dawley rats, after 2 weeks of subcutaneous genistein injections (250 mg=kg of body weight=day). Uterine weight, uterine-to-body weight ratio, femur weight, and femur-to-body weight ratio were all significantly increased with genistein in OVX rats. Body weight was significantly decreased with genistein in OVX rats. Genistein had no effect on the weights of heart, heart-to-body ratio, and fat pad but significantly decreased heart rate and pulse pressure. Genistein had no effect on cardiac GLUT4 protein, oxidative stress, plasma glucose, nonesterified fatty acids, or low-density lipoprotein levels; however, plasma insulin levels were significantly increased. Our results show that a 2-week genistein treatment produced favorable estrogen-like effects on some physical and physiological characteristics in OVX rats. However, based on our experimental conditions, the effects of genistein were not associated with changes in cardiac GLUT4 or oxidative stress.

show abstract

“…The extract did not affect the lobuloalveolar and duct apparatus of the ovx rats whereas estradiol (E2) containing food resulted in a massive stimulation of the lobuli and duct (Fig. 3a-f ) [26]. Sprague-Dawley rats treated with DMBA developed typical mammary tumor structures that were inhibited by oral administration of an isopropanolic CR extract [27].…”

Section: Cimicifuga Racemosa (Black Cohosh)mentioning

confidence: 99%

Black cohosh (Cimicifuga racemosa) is a non-estrogenic alternative to hormone replacement therapy

Wuttke¹,

Seidlová-Wuttke²

2015

Clin Phytosci

Self Cite

View full text Add to dashboard Cite

Hormone replacement therapy is still a popular and most effective treatment for vasomotor symptoms and bone loss prevention in the postmenopause but it is not without risks. This has driven many climacteric women to seek for alternatives, chiefly natural products. Phytoestrogens containing soy or red clover preparations, however, when taken at the recommended daily doses, proved to be ineffective to ameliorate climacteric complaints and to prevent osteoporosis. Cimicifuga racemosa (CR) preparations, on the other hand, have been shown to ease climacteric distress. There is a widespread, but false, belief that the efficacy of CR preparations is linked to the presence of phytoestrogens in the plant. This review aims at summarizing the available in vitro and in vivo evidence showing that compounds in CR extracts do not bind to oestrogen receptors and thus do not exert any estrogenic effects in the uterus and mammary gland, as shown in vivo in experiments on ovariectomized rats and clinically in postmenopausal women. Studies in ovariectomized rats and in women suffering from climacteric complaints have indicated that substances with neurotransmitter-like activities affect beneficially postmenopausal symptoms such as hot flushes. Some of these compounds, such as actein-like triterpenes with GABA-ergic activity and a serotonin analogue, are present and have been identified in the CR extracts. We conclude that these activities explain most likely the beneficial effects of CR extracts on climacteric complaints.

show abstract

Effects of Chronic Genistein Treatment in Mammary Gland, Uterus, and Vagina

Cited by 65 publications

References 50 publications

Rates and Risk Factors in Macrosomic Newborns among Non-Diabetic Parturients at Tiznit City, Morocco: A Case-Control Study

Rates and Risk Factors in Macrosomic Newborns among Non-Diabetic Parturients at Tiznit City, Morocco: A Case-Control Study

Genistein Induces Estrogen-Like Effects in Ovariectomized Rats but Fails to Increase Cardiac GLUT4 and Oxidative Stress

Black cohosh (Cimicifuga racemosa) is a non-estrogenic alternative to hormone replacement therapy

Contact Info

Product

Resources

About